Life in a bubble – droplet scienceIt’s a discovery that revolutionises our fundamental understanding of cells. Tiny droplets called condensates that form through weak interactions between proteins and RNA are at the heart of many key … more ➔
Is AMR the next, but hidden, crisis?With the coronavirus pandemic mounting, experts are warning of AMR as being the next, hidden crisis. more ➔
CRO opens new branch office in Berlin FGK Clinical Research GmbH opens a branch office in Berlin this month. The Berlin office will support the operative units at the German headquarters in Munich. more ➔
Playing God with the fates of cellsDreams of simple, reliable and scalable processes for the much-hyped cell therapy market have generated demand for cost-effective, GMP-compliant manufacturing methods. The drug-screening market is also … more ➔
The biotech boost – when, if not now... Despite the threat of a looming climate catastrophe, low oil prices and giant industrial conglomerates addicted to fossil resources continue to stifle industrial biotechnology products and innovation. … more ➔
Setting trends with eco-fashion Enzymes have been used widely for years to bleach textiles or shrink wool. However, the clothing sector is one of the world’s most polluting industries. And now fashion labels are turning increasingly … more ➔
Council presses EC to decide on genome edi... After years of regulatory deadlock concerning political decision making on genome-edited and genetically targeted mutational breeding, the European Council has demanded that the European Commission … more ➔
New players to step into the AMR fieldDespite challenging markets new players are entering the field to advance drug development in the fight against antimicrobial resistance. more ➔
The AMR business (Part II)SMEs active in antibiotic development are trying to adapt to the uncertain AMR business. Meanwhile, the European IMI AMR accelerator kicked off. more ➔
The AMR business (Part I)Antibiotic developers struggle with uncertain market conditions, weak reimbursement schemes and low turnover once a drug is approved. Experts are trying to figure out the best way to balance push and … more ➔
